To control the devastating group B meningococcal epidemic in New Zealand a strain-specific OMV vaccine (MeNZB) was extensively tested before vaccination of \textgreater1,000,000 people under 20 years. After the three-dose course 75\% of 6-8-month-old infants and 16-24-month-old toddlers showed four-fold increases in bactericidal antibodies. In 6-10-week-old infants a fourth dose was needed to obtain similar results. After primary vaccination, the antibody titre decline was most pronounced among the youngest but both young infants and toddlers showed a clear booster response to a fourth dose. MeNZB was safe and well tolerated. The comprehensive post-licensure safety surveillance revealed no safety concerns.
%0 Journal Article
%1 oster_immunogenicity_2007
%A Oster, P
%A O'Hallahan, J
%A Aaberge, I
%A Tilman, S
%A Ypma, E
%A Martin, D
%D 2007
%J Vaccine
%K Antibodies, B, Bacterial, Child, Humans, Infant, Infections, Meningococcal Neisseria New Pharmaceutical Preparations, Preschool, Safety Serogroup Vaccines, Zealand, meningitidis,
%N 16
%P 3075--9
%R 10.1016/j.vaccine.2007.01.023
%T Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand
%U http://www.ncbi.nlm.nih.gov/pubmed/17289223
%V 25
%X To control the devastating group B meningococcal epidemic in New Zealand a strain-specific OMV vaccine (MeNZB) was extensively tested before vaccination of \textgreater1,000,000 people under 20 years. After the three-dose course 75\% of 6-8-month-old infants and 16-24-month-old toddlers showed four-fold increases in bactericidal antibodies. In 6-10-week-old infants a fourth dose was needed to obtain similar results. After primary vaccination, the antibody titre decline was most pronounced among the youngest but both young infants and toddlers showed a clear booster response to a fourth dose. MeNZB was safe and well tolerated. The comprehensive post-licensure safety surveillance revealed no safety concerns.
@article{oster_immunogenicity_2007,
abstract = {To control the devastating group B meningococcal epidemic in New Zealand a strain-specific {OMV} vaccine {(MeNZB)} was extensively tested before vaccination of {\textgreater}1,000,000 people under 20 years. After the three-dose course 75\% of 6-8-month-old infants and 16-24-month-old toddlers showed four-fold increases in bactericidal antibodies. In 6-10-week-old infants a fourth dose was needed to obtain similar results. After primary vaccination, the antibody titre decline was most pronounced among the youngest but both young infants and toddlers showed a clear booster response to a fourth dose. {MeNZB} was safe and well tolerated. The comprehensive post-licensure safety surveillance revealed no safety concerns.},
added-at = {2011-03-11T10:05:34.000+0100},
author = {Oster, P and {O'Hallahan}, J and Aaberge, I and Tilman, S and Ypma, E and Martin, D},
biburl = {https://www.bibsonomy.org/bibtex/29c2c1bfd2d1a57006d03244e338d252f/jelias},
doi = {10.1016/j.vaccine.2007.01.023},
interhash = {20ce8dcd83d6c5eb3dc26a8205cb6325},
intrahash = {9c2c1bfd2d1a57006d03244e338d252f},
issn = {{0264-410X}},
journal = {Vaccine},
keywords = {Antibodies, B, Bacterial, Child, Humans, Infant, Infections, Meningococcal Neisseria New Pharmaceutical Preparations, Preschool, Safety Serogroup Vaccines, Zealand, meningitidis,},
month = apr,
note = {{PMID:} 17289223},
number = 16,
pages = {3075--9},
timestamp = {2011-03-11T10:06:11.000+0100},
title = {Immunogenicity and safety of a strain-specific {MenB} {OMV} vaccine delivered to under 5-year olds in New Zealand},
url = {http://www.ncbi.nlm.nih.gov/pubmed/17289223},
volume = 25,
year = 2007
}